Skip to main content

Psoriatic arthritis

RheumNow Podcast – with Special Guest Dr. Kathryn Dao (9.29.2023)

Sep 29, 2023

This week on the podcast, Dr. Jack Cush is joined by special guest, Dr. Kathryn Dao to review the news and journal reports from the past week on RheumNow.com. They discuss unmet needs in gout, obesity and CV disease in PsA and should you check ANCA antibodies in SLE?




  1. Painful

Read Article

Microvascular CV Disease with Severe Psoriasis

Sep 26, 2023

While comorbidities, including an increased cardiovascular (CV) risk, are associated with severe psoriasis, less is known about subclinical CV disease and when it occurs in patients with psoriasis. 



Coronary microvascular dysfunction (CMD) has been shown to be predictive of future

Read Article
Machine Learning May Diagnose Psoriatic Arthritis Earlier A machine learning approach was applied to two different population cohorts and was shown to be effective at the early identification of undiagnosed psoriatic arthritis (PsA). https://t.co/ecAF5OTgfr https://t.co/9R2ZZH3I7j

RheumNow Podcast with Special Guest Dr. Michael Weinblatt (9.22.2023)

Sep 22, 2023

Dr. Jack Cush is joined by Dr. Michael Weinblatt as they discuss this weeks news and journal reports, including difficult RA, HLA typing and abatacept responses and new regulatory decisions. 




  1. UCB has issued a press update on its pending application for the approval of their

Read Article

Machine Learning May Diagnose Psoriatic Arthritis Earlier

Sep 18, 2023

A machine learning approach was applied to two different population cohorts and was shown to be effective at the early identification of undiagnosed psoriatic arthritis (PsA).



It is estimated that PsA affects approximately 0.27% of the adult population, and 20% of those with with

Read Article
SAVE THE DATE! RheumNow Live will now be taking place in January! Who is joining us? https://t.co/EdrLp87Z81

Woeful Rheumatology Referrals

Sep 07, 2023

Early diagnosis of inflammatory arthritis (IA) is rooted in patient (self or MD) referrals. A recent analysis shows only a minority of rheumatology referrals had inflammatory arthritis, with only 21% were seen within the first 6 weeks of symptoms. 



A total of 1023 were patients

Read Article
SAVE THE DATE! RheumNow Live will now be taking place in January! Will you be there? https://t.co/cpfWvKaR1y
UK regulatory authority (MHRA) has granted marketing authorization for Bimzelx (bimekizumab), a dual inhibitor of IL-17A & IL-17F; approved in adults w/ active psoriatic arthritis or axial spondyloarthritis (+/- MTX). Prev approved in EU June 2023 https://t.co/Hp5W1t6Acz https://t.co/6tZ1DN8TVo
SAVE THE DATE! RheumNow Live will now be taking place in January! Will you be there? https://t.co/WCfBzthXvl
COSMOS: Guselkumab's Immunologic Benefits in Psoriatic Arthritis https://t.co/tFquWoITSn https://t.co/7vQl2a6Vvu
PRESTO Tool Predicts the Risk of PsA In research published in Arthritis & Rheumatology, investigators developed called PRESTO that identifies patients with psoriasis who face an elevated risk for developing pSa and may benefit from preventive therapies. https://t.co/hp8ygab41B https://t.co/EvMcabQJjd

COSMOS: Guselkumab's Immunologic Benefits in Psoriatic Arthritis

Aug 17, 2023

The IL-23 inhibitor guselkumab was studied in active psoriatic arthritis patients in the phase 3b COSMOS trial, and shown to be clinically effective while reducing multiple effector cytokines, including those associated with the IL-23/IL-17 pathway.

Read Article
UK study of 1,.3 million RMD (RA, PsA, FM) pts looked at opioid Rx 2006-2021. New opioid Rx incr 2006 to 2019, but incr most (4.5 fold) in FM from 3.4/10K in 2006 to 8.7 in 2018/2019 (falling to 5.9 in 2021). Overall less opioid use during the pandemic https://t.co/rNmk6AGMAX https://t.co/8XDFjFa5x9

The Adalimumab Biosimilar Glut

Aug 15, 2023

In 2023, three marketed biosimilars (Actemra, Stelara, Humira) had their patents expire, opening opportunities for multiple new biosimilars; but with competition comes a word salad of new drug names, confusion and nonsensical discounts.



By July 2023, nine adalimumab biosimilars (ADA-b

Read Article
PRESTO Tool Predicts the Risk of PsA In research published in Arthritis & Rheumatology, investigators developed called PRESTO that identifies patients with psoriasis who face an elevated risk for developing pSa and may benefit from preventive therapies. https://t.co/vJ7A178T9U https://t.co/W17zE8AsFU

Pizza and Rheumatoid Arthritis (8.11.2023)

Aug 11, 2023

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:




  1. Swedish study of 325 #AAV pts saw CVA in 35 pts (8%); CVA incidence=11.3/1000 PYs - this was higher than gen population [SIR 1.85). AAV CVA risk factors included age

Read Article
Patient Perspectives on Telemedicine Use During the Pandemic Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients. https://t.co/EJ5TkiDMcJ https://t.co/xBx7OIxf9h

PRESTO Tool Predicts the Risk of Psoriatic Arthritis

EurekAlert!
Aug 09, 2023

In research published in Arthritis & Rheumatology, investigators developed and validated a tool called PRESTO that

Read Article
Assessment of Psoriatic Arthritis: A Global Perspective Drs. Antoni Chan, Nelly Ziade and Ihsane Hmamouchi discuss POS1542 presented at EULAR 2023 in Milan, Italy https://t.co/mSNhAma78C https://t.co/dhikAgIW7t
HEALTH DISPARITIES: Lancet study shows from 2000-2019, all-cause mortality was signif. higher in the American Indian/Alaska Native (1028/100K) & Blacks (953·/100K) compared to Whites (802); but lower in Asians (442) & Latinos (595) https://t.co/g8Z3h6BYw8 https://t.co/Ckz1L3O0W7

English for the Biologically-Challenged (8.4.2023)

Aug 04, 2023

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.

Read Article
Tofacitinib in Polymyalgia Rheumatica (EAST PMR Study) An open-label, uncontrolled pilot trial has shown that JAK signaling is involved in the pathogenesis of PMR and that tofacitinib is as effective as glucocorticoids (GC) in patients with PMR. https://t.co/sJcq9lMP1l https://t.co/zvmPs3SdCw
RABBIT Registry Study 2470 pts (1,245 axSpA; 1,225 PsA) - moderate depressive Sxs in 8% & 21% w/ severe Sxs. Depressive Sxs were assoc w/ fatigue, not engaging in sports, & greater functional limitation - may affect perception of disease activity https://t.co/XTyzLF98BC https://t.co/8TLfRBK4lX
Synovial T cells from 20 pts Rx w/ immune checkpoint inhibitors who developed ICI-arthritis compared w/ synovial T cells from RA & PsA pts - showing clonal expansion of activated effector CD38hi,CD127−, CD8 T cells, w/ incr type I IFN-assoc transcripts https://t.co/vw2sOGL6jQ https://t.co/uDlt9dH4mQ
×